BioSpace News Archive

BioMed X and the Universitätsmedizin Mannheim announced today the publication of two manuscripts in the field of cancer immunology in the journal Science Advances.

MD Revolution announced that its partner, Cardiac Solutions achieved a 50% reduction in hospital cardiovascular readmission rates by using RevUp Remote Patient Monitoring and Chronic Care Management as part of their program.

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has completed its acquisition of C2i Genomics, Inc., adding whole-genome minimal residual disease (MRD) capabilities to its novel diagnostics platform.

Twist Bioscience Corporation and Element Biosciences, Inc. today announced a collaboration to develop the Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow for Element’s AVITI™ System.

bioAffinity Technologies today announced that Sandeep Bansal, M.D., Medical Director of Lung Innovations Network, has joined the Company’s Medical and Scientific Advisory Board.

Femasys Inc. today announced the appointment of Richard Spector to chief commercial officer (CCO), effective February 2024.

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today that the United States Patent and Trademark Office (USPTO) has allowed its patent application with claims covering the use of TNX-103 (oral levosimendan).

Vistagen today announced it will host a conference call and webcast on Tuesday, February 13, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2024 third quarter ended December 31, 2023 and provide a corporate update.

Cognition Therapeutics, Inc. announced that collaborators at the University of Edinburgh, Scotland published findings in the journal, Acta Neuropathologica, that provide new insight into the biology of Alzheimer’s disease that is consistent with our understanding of the role the σ-2 receptor has in regulating Aβ oligomer binding.

Jasper Therapeutics, Inc. announced today the pricing of its underwritten offering of 3,900,000 shares of its common stock.